Clinical trial
Role of Fcgamma Receptors in Immune Thrombocytopenia (ITP)
Name
BONNOTTE PARI 2013
Description
Immune thrombocytopenia (ITP) is an autoimmune disease characterized by a peripheral destruction of platelets responsible for bleedings.
Monocytes/macrophages play a double role by phagocyting platelets recognized by autoantibodies and by maintaining the autoimmune response via their antigen-presenting cell functions.
Fcgamma receptors (FcγR), that are represented by activating receptors (FcγRI, FcγRIIa, FcγRIII) and an inhibiting one (FcγRIIb), are involved in the regulation of macrophages and have been reported to be dysregulated in autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematous.
The aim of this study is to compare the expression of FcγR in patients with ITP on circulating monocytes and on splenic macrophages.
Trial arms
Trial start
2014-10-02
Estimated PCD
2024-09-01
Trial end
2024-09-01
Status
Recruiting
Treatment
blood sample
Arms:
control, patient
spleen sample
Arms:
control, patient
Size
70
Primary endpoint
1. The expressions of the activating FcγRs and the inhibiting receptor (FcγRIIb) on monocytes will be compared between ITP patients at diagnosis and controls - physiological parameter
through study completion, an average of 2 years
Eligibility criteria
Inclusion Criteria:
ITP group
* Patients who have provided written consent
* Patients over 18 years
* Patients with national health insurance
* Patients with ITP, defined as thrombocytopenia \< 100 G/L, after exclusion of infection- or drug-related thrombocytopenia and malignant hemopathy.
Control Group
* Persons who have provided a written consent
* Persons over 18 years
* Persons with national health insurance
* Persons without autoimmune disease
Exclusion Criteria:
* Patients under guardianship
* Pregnancy
Protocol
{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'CASE_CONTROL', 'timePerspective': 'PROSPECTIVE'}, 'enrollmentInfo': {'count': 70, 'type': 'ESTIMATED'}}
Updated at
2024-02-20
1 organization
1 indication
Organization
Centre Hospitalier Universitaire DijonIndication
Immune Thrombocytopenia